Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs" title="" class="btn" data-container="body" data-html="true" data-id="252830" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Talus Bio"> 3,709
Activities
Technologies
Entity types
Location
550 17th Ave #550, Seattle, WA 98122, USA
Seattle
United States of America
Employees
Scale: 11-50
Estimated: 23
Engaged corporates
2Added in Motherbase
3 weeks, 5 days agoGene regulator profiling in live cells for drug development
Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology.
Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.
As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery:
- Developing internal programs against previously undruggable gene regulators in
cancers with poor standard of care
- Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs
Talus Bioscience combines functional proteomics, automated biology, and machine learning to target hard-to-treat transcription factors driving cancer & beyond.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() J.P. Morgan Bank | J.P. Morgan Bank | Other 14 Jan 2025 | | |
![]() Y Combinator Startup accelerator & VC, Venture Capital and Private Equity Principals | Y Combinator Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 22 Aug 2023 | |